MedTrace Logo

Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 in Healthy Volunteers

NCT00940212 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-12-10

No results posted yet for this study

Summary

The primary aim of this study is to investigate the safety and tolerability of AZD2423 single doses in healthy volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

AZD2423

oral, single administration

DRUG

Placebo

oral administration and single dose

Sponsors & Collaborators

Principal Investigators

  • Rainard Fuhr, MD · PAREXEL Early Phase Clinical Uniit, Berlin Germany

  • Anders Neijber · AstraZeneca R&D Södertälje

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00940212 on ClinicalTrials.gov